Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Fundamental Analysis

NASDAQ:PRFX - Nasdaq - IL0011651580 - Common Stock - Currency: USD

1.87  -0.08 (-4.1%)

Fundamental Rating

2

PRFX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. PRFX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRFX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRFX has reported negative net income.
In the past year PRFX has reported a negative cash flow from operations.
In the past 5 years PRFX always reported negative net income.
In the past 5 years PRFX always reported negative operating cash flow.
PRFX Yearly Net Income VS EBIT VS OCF VS FCFPRFX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

PRFX has a worse Return On Assets (-322.39%) than 92.93% of its industry peers.
PRFX has a Return On Equity of -799.78%. This is amonst the worse of the industry: PRFX underperforms 80.81% of its industry peers.
Industry RankSector Rank
ROA -322.39%
ROE -799.78%
ROIC N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRFX Yearly ROA, ROE, ROICPRFX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

PRFX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRFX Yearly Profit, Operating, Gross MarginsPRFX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, PRFX has more shares outstanding
Compared to 5 years ago, PRFX has more shares outstanding
There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRFX Yearly Shares OutstandingPRFX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
PRFX Yearly Total Debt VS Total AssetsPRFX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -26.82, we must say that PRFX is in the distress zone and has some risk of bankruptcy.
PRFX's Altman-Z score of -26.82 is on the low side compared to the rest of the industry. PRFX is outperformed by 87.37% of its industry peers.
There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.82
ROIC/WACCN/A
WACCN/A
PRFX Yearly LT Debt VS Equity VS FCFPRFX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.81 indicates that PRFX should not have too much problems paying its short term obligations.
The Current ratio of PRFX (1.81) is worse than 61.11% of its industry peers.
PRFX has a Quick Ratio of 1.81. This is a normal value and indicates that PRFX is financially healthy and should not expect problems in meeting its short term obligations.
PRFX has a Quick ratio of 1.81. This is comparable to the rest of the industry: PRFX outperforms 42.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.81
PRFX Yearly Current Assets VS Current LiabilitesPRFX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

PRFX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.23%, which is quite impressive.
EPS 1Y (TTM)81.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRFX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.63% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRFX Yearly EPS VS EstimatesPRFX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRFX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRFX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRFX Price Earnings VS Forward Price EarningsPRFX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRFX Per share dataPRFX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as PRFX's earnings are expected to grow with 24.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.63%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRFX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAINREFORM LTD

NASDAQ:PRFX (5/21/2025, 8:00:00 PM)

1.87

-0.08 (-4.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-13 2025-08-13
Inst Owners4.97%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.53M
Analysts43.33
Price TargetN/A
Short Float %6.23%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-32.16
EYN/A
EPS(NY)-49.2
Fwd EYN/A
FCF(TTM)-6.68
FCFYN/A
OCF(TTM)-6.68
OCFYN/A
SpS0
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -322.39%
ROE -799.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.81
Altman-Z -26.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.96%
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-88.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.97%
OCF growth 3YN/A
OCF growth 5YN/A